Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Genitourinary Cancers
How do you counsel NCCN low and very low risk prostate cancer patients who receive a high risk DECIPHER score?
Related Questions
Would you offer salvage radiation for a local recurrence of prostate cancer that was initially treated with SBRT?
What is the risk of local recurrence in a high grade muscle invasive bladder cancer (MIBC) s/p incomplete TURBT treated with concurrent chemoradiation compared to a complete TURBT?
Given results of BCON trial, do you add carbogen and nicotinamide for patients receiving definitive radiotherapy for bladder cancer, particularly for non-cisplatin eligible candidates?
Would you include the entire bladder in the treatment field of a patient with a history of T1 bladder cancer s/p intravesical therapy who is now being planned for chemoradiation for a T3N1 rectal cancer?
How do you dose or sequence therapy to overcome radioresistance from oligometastatic disease from RCC?
Would you recommend adjuvant radiation for a mucinous urachal adenocarcinoma s/p partial cystectomy and LN sampling with negative margins?
Are there any patient characteristics that make you change fractionation when treating per STAMPEDE?
Is there a limit to the size of a prostate cancer oligometastasis for SBRT?
How would you manage a patient with a locally advanced bladder cancer s/p TURBT who had prior radiation?
What are your top takeaways from ASCO GU 2024?
